0000000000654364

AUTHOR

Imma Attolico

showing 1 related works from this author

Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.

2020

OncologyAdultMalemedicine.medical_specialtyAdolescentMyelogenouschemistry.chemical_compoundInternal medicineLeukemia Myelogenous Chronic BCR-ABL PositiveMedicineHumansChildProtein Kinase Inhibitorsbusiness.industryPonatinibLow doseFollow up studiesImidazolesMyeloid leukemiaInfantHematologymedicine.diseasePyridazinesLeukemiachemistryChild PreschoolFemalebusinessFollow-Up StudiesAmerican journal of hematology
researchProduct